AAPL293.08-1.22 (-0.41%) ▼|ABBV234.89+0.13 (+0.06%) ▲|ABT90.49-0.04 (-0.04%) ▼|ACN129.15+2.14 (+1.68%) ▲|ADBE196.57-0.86 (-0.44%) ▼|AMAT588.97+3.09 (+0.53%) ▲|AMD519.74-0.11 (-0.02%) ▼|AMGN351.43+4.42 (+1.27%) ▲|AMT174.46-4.92 (-2.74%) ▼|AMZN234.27+0.16 (+0.07%) ▲|AVGO382.07+1.92 (+0.51%) ▲|AXP342.56+4.78 (+1.42%) ▲|BA220.25+3.54 (+1.63%) ▲|BAC57.73-0.18 (-0.31%) ▼|BKNG181.25+12.31 (+7.29%) ▲|BLK982.60-32.73 (-3.22%) ▼|BMY55.00-0.53 (-0.95%) ▼|BNY143.56-3.73 (-2.53%) ▼|BRK-B494.81+2.00 (+0.41%) ▲|C143.59-1.38 (-0.95%) ▼|CAT994.45+10.21 (+1.04%) ▲|CL91.88+0.45 (+0.49%) ▲|CMCSA22.64-0.16 (-0.70%) ▼|COF200.48+2.67 (+1.35%) ▲|COP106.92-3.05 (-2.77%) ▼|COST961.09+3.41 (+0.36%) ▲|CRM152.76-0.66 (-0.43%) ▼|CSCO119.73-1.42 (-1.17%) ▼|CVS101.87+0.30 (+0.30%) ▲|CVX171.45-4.53 (-2.57%) ▼|DE600.75+8.81 (+1.49%) ▲|DHR188.87+9.90 (+5.53%) ▲|DIS101.12-2.41 (-2.33%) ▼|DUK126.53+1.48 (+1.18%) ▲|EMR141.44-1.70 (-1.19%) ▼|FDX316.83-0.41 (-0.13%) ▼|GD344.32-6.02 (-1.72%) ▼|GE365.88+9.41 (+2.64%) ▲|GEV1,057.65+22.67 (+2.19%) ▲|GILD125.16+0.11 (+0.09%) ▲|GM78.95+0.00 (+0.00%) ▲|GOOG345.04-1.04 (-0.30%) ▼|GOOGL345.29-0.80 (-0.23%) ▼|GS1,076.91-17.53 (-1.60%) ▼|HD342.86+18.41 (+5.67%) ▲|HON227.42+5.05 (+2.27%) ▲|IBM262.96-1.98 (-0.75%) ▼|INTC131.65-0.63 (-0.48%) ▼|INTU262.24+4.19 (+1.62%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ241.00+1.92 (+0.80%) ▲|JPM333.45-0.69 (-0.21%) ▼|KO80.60+0.29 (+0.36%) ▲|LIN515.73+3.47 (+0.68%) ▲|LLY1,117.26+10.18 (+0.92%) ▲|LMT491.64-12.03 (-2.39%) ▼|LOW221.45+7.91 (+3.70%) ▲|LRCX374.80+3.47 (+0.93%) ▲|MA494.41+6.34 (+1.30%) ▲|MCD273.88+2.22 (+0.82%) ▲|MDLZ61.74+0.68 (+1.11%) ▲|MDT80.13-0.50 (-0.62%) ▼|META557.67-4.53 (-0.81%) ▼|MMM165.91+4.07 (+2.51%) ▲|MO72.07+0.46 (+0.64%) ▲|MRK120.60+1.00 (+0.84%) ▲|MS219.86-6.17 (-2.73%) ▼|MSFT365.46-8.48 (-2.27%) ▼|MU1,048.51-3.26 (-0.31%) ▼|NEE87.62+1.19 (+1.38%) ▲|NFLX71.84-0.98 (-1.35%) ▼|NKE41.82-0.56 (-1.32%) ▼|NOW93.80-2.14 (-2.23%) ▼|NVDA199.00-1.00 (-0.50%) ▼|ORCL157.53-7.63 (-4.62%) ▼|PEP142.27+0.22 (+0.15%) ▲|PFE24.04-0.68 (-2.75%) ▼|PG152.04+1.18 (+0.78%) ▲|PLTR113.50-3.20 (-2.74%) ▼|PM178.78+0.09 (+0.05%) ▲|QCOM197.41-6.72 (-3.29%) ▼|RTX185.06-1.33 (-0.71%) ▼|SBUX103.53+2.48 (+2.45%) ▲|SCHW91.39-1.78 (-1.91%) ▼|SO95.78+0.85 (+0.90%) ▲|SPG222.15+5.41 (+2.50%) ▲|T22.37-0.44 (-1.93%) ▼|TMO492.20+22.85 (+4.87%) ▲|TMUS180.79-3.78 (-2.05%) ▼|TSLA375.53-6.08 (-1.59%) ▼|TXN303.11-1.25 (-0.41%) ▼|UBER73.85+4.18 (+6.00%) ▲|UNH405.80-3.45 (-0.84%) ▼|UNP259.96+1.35 (+0.52%) ▲|UPS106.14+0.31 (+0.29%) ▲|USB60.11+0.06 (+0.10%) ▲|V332.23+3.75 (+1.14%) ▲|VZ45.68-1.05 (-2.25%) ▼|WFC84.30+0.17 (+0.20%) ▲|WMT119.00-0.42 (-0.35%) ▼|XOM136.90-2.83 (-2.03%) ▼|AAPL293.08-1.22 (-0.41%) ▼|ABBV234.89+0.13 (+0.06%) ▲|ABT90.49-0.04 (-0.04%) ▼|ACN129.15+2.14 (+1.68%) ▲|ADBE196.57-0.86 (-0.44%) ▼|AMAT588.97+3.09 (+0.53%) ▲|AMD519.74-0.11 (-0.02%) ▼|AMGN351.43+4.42 (+1.27%) ▲|AMT174.46-4.92 (-2.74%) ▼|AMZN234.27+0.16 (+0.07%) ▲|AVGO382.07+1.92 (+0.51%) ▲|AXP342.56+4.78 (+1.42%) ▲|BA220.25+3.54 (+1.63%) ▲|BAC57.73-0.18 (-0.31%) ▼|BKNG181.25+12.31 (+7.29%) ▲|BLK982.60-32.73 (-3.22%) ▼|BMY55.00-0.53 (-0.95%) ▼|BNY143.56-3.73 (-2.53%) ▼|BRK-B494.81+2.00 (+0.41%) ▲|C143.59-1.38 (-0.95%) ▼|CAT994.45+10.21 (+1.04%) ▲|CL91.88+0.45 (+0.49%) ▲|CMCSA22.64-0.16 (-0.70%) ▼|COF200.48+2.67 (+1.35%) ▲|COP106.92-3.05 (-2.77%) ▼|COST961.09+3.41 (+0.36%) ▲|CRM152.76-0.66 (-0.43%) ▼|CSCO119.73-1.42 (-1.17%) ▼|CVS101.87+0.30 (+0.30%) ▲|CVX171.45-4.53 (-2.57%) ▼|DE600.75+8.81 (+1.49%) ▲|DHR188.87+9.90 (+5.53%) ▲|DIS101.12-2.41 (-2.33%) ▼|DUK126.53+1.48 (+1.18%) ▲|EMR141.44-1.70 (-1.19%) ▼|FDX316.83-0.41 (-0.13%) ▼|GD344.32-6.02 (-1.72%) ▼|GE365.88+9.41 (+2.64%) ▲|GEV1,057.65+22.67 (+2.19%) ▲|GILD125.16+0.11 (+0.09%) ▲|GM78.95+0.00 (+0.00%) ▲|GOOG345.04-1.04 (-0.30%) ▼|GOOGL345.29-0.80 (-0.23%) ▼|GS1,076.91-17.53 (-1.60%) ▼|HD342.86+18.41 (+5.67%) ▲|HON227.42+5.05 (+2.27%) ▲|IBM262.96-1.98 (-0.75%) ▼|INTC131.65-0.63 (-0.48%) ▼|INTU262.24+4.19 (+1.62%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ241.00+1.92 (+0.80%) ▲|JPM333.45-0.69 (-0.21%) ▼|KO80.60+0.29 (+0.36%) ▲|LIN515.73+3.47 (+0.68%) ▲|LLY1,117.26+10.18 (+0.92%) ▲|LMT491.64-12.03 (-2.39%) ▼|LOW221.45+7.91 (+3.70%) ▲|LRCX374.80+3.47 (+0.93%) ▲|MA494.41+6.34 (+1.30%) ▲|MCD273.88+2.22 (+0.82%) ▲|MDLZ61.74+0.68 (+1.11%) ▲|MDT80.13-0.50 (-0.62%) ▼|META557.67-4.53 (-0.81%) ▼|MMM165.91+4.07 (+2.51%) ▲|MO72.07+0.46 (+0.64%) ▲|MRK120.60+1.00 (+0.84%) ▲|MS219.86-6.17 (-2.73%) ▼|MSFT365.46-8.48 (-2.27%) ▼|MU1,048.51-3.26 (-0.31%) ▼|NEE87.62+1.19 (+1.38%) ▲|NFLX71.84-0.98 (-1.35%) ▼|NKE41.82-0.56 (-1.32%) ▼|NOW93.80-2.14 (-2.23%) ▼|NVDA199.00-1.00 (-0.50%) ▼|ORCL157.53-7.63 (-4.62%) ▼|PEP142.27+0.22 (+0.15%) ▲|PFE24.04-0.68 (-2.75%) ▼|PG152.04+1.18 (+0.78%) ▲|PLTR113.50-3.20 (-2.74%) ▼|PM178.78+0.09 (+0.05%) ▲|QCOM197.41-6.72 (-3.29%) ▼|RTX185.06-1.33 (-0.71%) ▼|SBUX103.53+2.48 (+2.45%) ▲|SCHW91.39-1.78 (-1.91%) ▼|SO95.78+0.85 (+0.90%) ▲|SPG222.15+5.41 (+2.50%) ▲|T22.37-0.44 (-1.93%) ▼|TMO492.20+22.85 (+4.87%) ▲|TMUS180.79-3.78 (-2.05%) ▼|TSLA375.53-6.08 (-1.59%) ▼|TXN303.11-1.25 (-0.41%) ▼|UBER73.85+4.18 (+6.00%) ▲|UNH405.80-3.45 (-0.84%) ▼|UNP259.96+1.35 (+0.52%) ▲|UPS106.14+0.31 (+0.29%) ▲|USB60.11+0.06 (+0.10%) ▲|V332.23+3.75 (+1.14%) ▲|VZ45.68-1.05 (-2.25%) ▼|WFC84.30+0.17 (+0.20%) ▲|WMT119.00-0.42 (-0.35%) ▼|XOM136.90-2.83 (-2.03%) ▼|
20.6 C
New York
Thursday, June 25, 2026

Tag: FDA

newssourceFORcompanyinformationcontent1marketreleases

Statement from the Alzheimer’s Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder

The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ --...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.

URGN SHAREHOLDERS: UroGen Pharma Ltd. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 28 Deadline (NASDAQ:URGN)

UroGen Pharma Ltd. investors that lost money are notified to contact BFA Law before July 28, 2025 securities fraud class action deadline.

ROCKET ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Rocket Pharmaceuticals, Inc. and Encourages Investors to...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ:RCKT) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Rocket securities between February 27, 2025 to May 26, 2025, both dates inclusive (the “Class Period”). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

RCKT Investor Notice: Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Rocket Pharmaceuticals, Inc.

Robbins LLP is Investigating Allegations that Rocket Pharmaceuticals, Inc. (RCKT) Misled Investors Regarding the Viability and Efficacy of RP-A501

DRI Healthcare Trust Comments on FDA Delay for KalVista Pharmaceuticals’ Sebetralstat PDUFA Goal Date Due to FDA Resourcing Constraints

- FDA decision anticipated within four weeks - TORONTO, June 13, 2025 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust") today announced KalVista Pharmaceuticals...

Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego

- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten...

Foundation CEO Provides Expert Testimony to U.S. Senate as Outside Witness on Vision Research Funding

Jason Menzo Urges Robust FY2026 Funding for National Eye Institute and Protection of Its Independent Status COLUMBIA, Md., June 13, 2025 /PRNewswire/ -- The Foundation Fighting...

Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach

HERZLIYA, Israel and CALGARY, AB, June 13, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a...

PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy

               

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFDA

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers